- June 9, 2026
Ailux Presents Preclinical Data on AI-optimized, CD3-Masked CD19×BCMA T-Cell Engager at EULAR 2026
SHANGHAI, LONDON & SOMERVILLE — June 9, 2026 — Ailux, an AI-native biotech company, today announced preclinical data on its AI-optimized, CD3-masked CD19×BCMA T-cell engager presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress in London. These data demonstrate that the company’s CD3-masked CD19×BCMA TCE achieves deep and broad B-cell depletion across preclinical models, while maintaining low, transient cytokine release. The molecule is designed for autoimmune diseases, where the goal is to achieve meaningful immune reset with carefully controlled T-cell activation.
Presentation Details
Poster Number: POS1144
Title: A CD19/BCMA Dual-Targeting T-Cell Engager Enables Deep B-Cell Depletion with Low Cytokine Release in Preclinical Models
Session: Poster View VIII — Saturday, June 6, 2026, 10:15 CET
Presenter: Dr. Barry Duplantis, Senior Vice President of Business Development
Key preclinical findings from Poster POS1144 include:- Target-dependent T-cell activation: The CD3-masked TCE showed minimal baseline CD3 binding and T-cell activation, while engaging strongly in the presence of CD19- and/or BCMA-expressing target cells.
- Potent B-cell depletion with low cytokine release: Ex vivo, the molecule potently depleted autologous B cells in PBMCs from systemic lupus erythematosus (SLE) donors. In cynomolgus monkeys, a single 5 mg/kg subcutaneous dose produced deep and broad depletion of peripheral and tissue B cells with low, transient IL-6 and TNF-α release.
- Subcutaneous exposure profile: In cynomolgus monkeys, the molecule showed stable serum half-life and high bioavailability, supporting its potential for subcutaneous administration.
Alex Li, Chief Executive Officer of Ailux stated: “Autoimmune diseases require therapies which can help achieve ‘immune reset’ while maintaining carefully controlled immune activation. Our EULAR data show that Ailux’s CD3-masked CD19×BCMA TCE can drive deep and broad depletion of B cells with low cytokine release. Equally important, this molecule showcases the power of our AI platform to generate proprietary, adaptable binder arms that can enable potentially best-in-class multispecific therapeutics.”
About Ailux
Ailux is an AI-native biotech company headquartered in Shanghai and a wholly-owned subsidiary of XtalPi (2228.HK), a global leader in building the AI & robotics infrastructure for life sciences and beyond. Established as an independent operation five years ago with its own dedicated team, platforms, and pipeline, Ailux combines proprietary AI biologics platforms with a 30,000 square foot wet lab to discover and engineer next-generation biologics across multiple therapeutic areas.
The company’s global team of approximately 150 spans China, the UK, and the US, drawing on the distinct strengths of each geography. Ailux has collaborated with Eli Lilly, Johnson & Johnson, and UCB, and is now advancing its own pipeline with the first programs expected to enter clinical development by 2027.